Tyme Technologies Inc

F:RFL

Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. The company is headquartered in Bedminster, New Jersey and currently employs 17 full-time employees. The company went IPO on 2012-05-25. The firm is focused on developing cancer metabolism-based therapies (CMBTs) for a range of solid tumors and hematologic cancers. The firm's lead clinical CMBT compound, SM-88, is an oral investigational modified tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cell's key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. The company is also developing SM-88i, an injectable formulation of SM-88 for the treatment of multiple oncology indications. Its TYME-18, is a pre-clinical CMBT designed for the intra-tumoral delivery of the treatment and increase the permeability of cancer cells, while delivering a therapy having selective cytotoxic effect on the tumor. Its TYME-19, is an oral, synthetically produced member of the bile acid family that is being developed for the potential treatment of COVID-19.